Showing 4351-4360 of 9153 results for "".
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- New Algorithm Helps Detect Aggressive Basal Cell Carcinoma for Optimal Treatmenthttps://practicaldermatology.com/news/new-algorithm-helps-detect-aggressive-basal-cell-carcinoma-optimal-treatment/2467648/An algorithm can help healthcare professionals recognize which patients have a highly aggressive form of basal cell carcinoma (BCC) of the face. These are the findings of a study conducted at the University of Gothenburg. If more BCCs are correctly identified as high-risk, the patients can direct
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- ZORYVE Cream 0.15% for AD Commercially Available This Weekhttps://practicaldermatology.com/news/zoryve-cream-015-ad-commercially-available-week/2467570/Arcutis Biotherapeutics announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild-to-moderate atopic dermatitis in adults and children down to age 6 in the United States, along with a co-promotion agreement with Kowa Pharmaceuticals America, Inc. ZORYVE is a o
- Committee Recommends Expanded Indications for Spesolimab, Targeting Generalized Pustular Psoriasishttps://practicaldermatology.com/news/spevigo-gets-expanded-indication-generalized-pustular-psoriasis-treatment-and-prevention/2467564/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval expanded indications for spesolimab (SPEVIGO®), according to a press release. A humanized selective IgG1 antibody targeting the interleu
- Cemiplimab Shows Promising Results in Refractory cSCC Patientshttps://practicaldermatology.com/news/cemiplimab-shows-promising-results-refractory-cscc-patients/2467554/New research suggests cemiplimab is safe and effective in patients with refractory locally advanced (LA) and metastatic cutaneous squamous cell carcinoma (cSCC). Researchers for the retrospective single-center Canadian study sought to characterize the real-world use of cemiplimab in pati
- DART Releases New Clinical Guidelines for Nonmelanoma Skin Cancer Treatmenthttps://practicaldermatology.com/news/dart-releases-new-clinical-guidelines-nonmelanoma-skin-cancer-treatment/2467534/The Dermatology Association of Radiation Therapy (DART) has published new clinical guidelines for the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) using image-guided superficial radiation therapy (IGSRT), according to a news release. The guidelines, developed
- Commentary: Beware Impact of TikTok's Algorithm on Dermatological Information Disseminationhttps://practicaldermatology.com/news/commentary-beware-impact-tiktoks-algorithm-dermatological-information-dissemination/2467491/A recent commentary in The Journal of Drugs in Dermatology exploring concerns about the dissemination of dermatological information on T
- Study: Crotoxin Demonstrates Efficacy Against Melanoma with Reduced Toxicityhttps://practicaldermatology.com/news/crotoxin-demonstrates-efficacy-against-melanoma-reduced-toxicity/2467490/A new study in Frontiers in Pharmacology indicated that crotoxin (CTX), a component of snake venom, was associated with antiproliferative effects on melanoma cells. "Melanoma, a highly aggressive skin cancer originating in melanocytes, poses a significant threat due to its metast